10 Unstoppable Stocks That Could Double Your Money

6. Edgewise Therapeutics Inc. (NASDAQ:EWTX)

1-Year Return: 31%

Upside Potential: 113%

Number of Hedge Fund Holders: 49

Edgewise Therapeutics Inc. operates (NASDAQ:EWTX) as a clinical-stage biotech company that creates precise therapeutic solutions for uncommon and critical muscular disorders. The company currently focuses on EDG-5506 as its primary drug candidate because it aims to stop skeletal muscle damage in patients with DMD and BMD.

In addition to EDG-5506, the company is advancing EDG-7500, a cardiovascular candidate for obstructive and non-obstructive hypertrophic cardiomyopathy (HCM), expanding its pipeline into another area of significant unmet medical need. Edgewise is committed to discovering and commercialising innovative treatments for muscle-related diseases with limited current options. The company maintains a strong financial position as of Q4 2024, having $470 million in cash while being debt-free, which provides ample funding for its active clinical research programs.

A Scotiabank analyst recently initiated coverage on Edgewise with a price target of $50 along with an Outperform rating because they see promising opportunities ahead in the company’s pipeline. The analyst highlighted promising early clinical data from sevasemten, which is being studied for both Becker and Duchenne muscular dystrophy, and EDG-7500 for cardiomyopathy. He views both programs as potential multi-billion-dollar opportunities and expects positive pipeline momentum to continue as the company progresses towards commercialisation in the near term.